» Articles » PMID: 20176655

Establishment and Characterization of 13 Human Colorectal Carcinoma Cell Lines: Mutations of Genes and Expressions of Drug-sensitivity Genes and Cancer Stem Cell Markers

Overview
Journal Carcinogenesis
Specialty Oncology
Date 2010 Feb 24
PMID 20176655
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Thirteen human colorectal cancer (CRC) cell lines were established from 10 primary tumors and 3 metastatic tumors obtained from 13 Korean patients. Characteristics of the cell lines including morphology in vivo and in vitro; mutations of the K-ras, p53, APC and MMR genes and microsatellite instability (MSI) status in vitro were determined. Expression of drug-sensitivity genes including MDR1, MXR, MRP1 and COX2 was also analyzed. The cell lines were unique as judged by DNA fingerprinting using 16 short tandem repeats. Eleven of the cell lines grew as adherent populations and the remaining two as floating aggregates. None of the cell lines were contaminated with Mycoplasma or bacteria. All cell lines showed high viability with relatively long doubling times. Six cell lines contained mutations at K-ras. Seven cell lines displayed p53 gene missense, nonsense and frameshift mutations. MSI was found in three cell lines and two cell lines with an MSI-high phenotype-possessed hMLH1 mutations. Nine cell lines had an APC mutation. MRP1 was highly expressed in all cell lines, and high expression of MDR1, MXR and COX2 evident in eight, six and six cell lines, respectively. Embryonal stem cell markers (MELK, SOX4 and OCT4) were expressed in most of cell lines. The cancer stem cell biomarkers CD133, CD44 and Lgr5 were expressed in 12, 13 and 13 cell lines, respectively. The presently well-characterized CRC cell lines should be useful in investigations of the biological characteristics of CRC, particularly for investigations related to gene alterations associated with CRC and biology of cancer stem cells.

Citing Articles

Model systems to study tumor-microbiome interactions in early-onset colorectal cancer.

Richter K, Wrage M, Krekeler C, De Oliveira T, Conradi L, Menck K EMBO Mol Med. 2025; 17(3):395-413.

PMID: 39948421 PMC: 11903813. DOI: 10.1038/s44321-025-00198-3.


Targeting MELK in tumor cells and tumor microenvironment: from function and mechanism to therapeutic application.

Su P, Lu Q, Wang Y, Mou Y, Jin W Clin Transl Oncol. 2024; .

PMID: 39187643 DOI: 10.1007/s12094-024-03664-5.


Establishment of primary prostate epithelial and tumorigenic cell lines using a non-viral immortalization approach.

Lange S, Kuntze A, Wustmann N, Reckers T, Humberg V, Dirks W Biol Res. 2024; 57(1):21.

PMID: 38704600 PMC: 11069155. DOI: 10.1186/s40659-024-00507-z.


Preclinical Repurposing of Sitagliptin as a Drug Candidate for Colorectal Cancer by Targeting //-Centered Signaling Hub.

Shih J, Wu A, Mokgautsi N, Wei P, Huang Y Int J Mol Sci. 2024; 25(1).

PMID: 38203779 PMC: 10778938. DOI: 10.3390/ijms25010609.


Enhanced Therapeutic Effects of Lu-DOTA-M5A in Combination with Heat Shock Protein 90 Inhibitor Onalespib in Colorectal Cancer Xenografts.

Mohajershojai T, Spangler D, Chopra S, Frejd F, Yazaki P, Nestor M Cancers (Basel). 2023; 15(17).

PMID: 37686514 PMC: 10486833. DOI: 10.3390/cancers15174239.